免疫性血小板减少症全球影响调查:患者与医生对诊断、症状及治疗的认知
I-WISh 是一项探索性横断面调查,纳入 13 个国家 1507 例患者和 472 名医生,评估免疫性血小板减少症(ITP)的多方面影响。疲劳是患者认为最常见和最严重的症状,但医生优先级较低。患者与医生在诊断、症状和治疗使用上总体一致,但在疲劳等方面存在差异。
要点
- 疲劳是患者认为最常见(58%)和最严重(73%)的症状,但仅 30% 医生给予高优先级。
- 医生认同限制糖皮质激素用于新诊断或首次复发患者,复发后增加使用 TPO-RA 和抗 CD20。
核心结论
- 患者与医生对 ITP 总体症状负担的认知基本一致,但在疲劳等方面存在差异。
研究设计与样本
- 探索性横断面调查,纳入 13 个国家 1507 例患者和 472 名医生。
主要发现
- 患者将疲劳评为诊断时最常见(58%)和最严重(73%)的症状。
- 医生对疲劳的优先级较低(30%)。
- 疲劳是调查完成时少数持续存在的症状之一(患者 50%,医生 65%)。
- 疲劳是患者最希望解决的症状(46%)。
临床怎么用
- 应重视疲劳对 ITP 患者的影响,将其纳入治疗目标设定和共享决策。
- 医生认同限制糖皮质激素用于新诊断或首次复发患者,复发后增加使用 TPO-RA 和抗 CD20。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune thrombocytopenia (ITP) is now well-known to reduce patients' health-related quality of life. However, data describing which signs and symptoms patients and physicians perceive as having the greatest impact are limited, as is understanding the full effects of ITP treatments. I-WISh (ITP World Impact Survey) was an exploratory, cross-sectional survey designed to establish the multifaceted impact of ITP, and its treatments, on patients' lives. It focused on perceptions of 1507 patients and 472 physicians from 13 countries regarding diagnostic pathway, frequency and severity of signs and symptoms, and treatment use. Twenty-two percent of patients experienced delayed diagnosis (caused by several factors), 73% of whom felt anxious as a result. Patients rated fatigue among the most frequent, severe symptom associated with ITP at diagnosis (58% most frequent; 73% most severe), although physicians assigned it lower priority (30%). Fatigue was one of the few symptoms persisting at survey completion (50% and 65%, respectively) and was the top symptom patients wanted resolved (46%). Participating physicians were experienced at treating ITP, thereby recognizing the need to limit corticosteroid use to newly-diagnosed or first-relapse patients and espoused increased use of thrombopoietin receptor agonists and anti-CD20 after relapse in patients with persistent/chronic disease. Patient and physicians were largely aligned on diagnosis, symptoms, and treatment use. I-WISh demonstrated that patients and physicians largely align on overall ITP symptom burden, with certain differences, for example, fatigue. Understanding the emotional and clinical toll of ITP on the patient will facilitate shared decision-management, setting and establishment of treatment goals and disease stage-appropriate treatment selection.
引用
- Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2020. PMID: 33170956. doi:10.1002/ajh.26045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。